Abstract
Although animal studies have shown that tumor antigen (TA)-pulsed dendritic cell (DC)-based vaccines can mediate antitumor effects in vivo, human clinical trials utilizing this strategy have thus far had only modest success. In an effort to improve the efficacy of tumor vaccines, numerous investigators have explored the genetic engineering of DC to impart cytokine or TA-expression capability on DC. These efforts have focused on enhancing TA presentation and as well as subsequent T-cell activation and expansion. This chapter reviews recent progress in studies aimed to potentiate the efficacy of DC-based vaccines by genetic engineering of DCs with cDNAs encoding immuno-stimulatory cytokine-genes or TAs.
Keywords: DC-based vaccines, tumor antigens, gene-silencing, GM-CSF, Immunological Microenvironment
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Manipulation of Dendritic Cells for Tumor Immunity
Volume: 6 Issue: 2
Author(s): Hideho Okada and Lisa H. Butterfield
Affiliation:
Keywords: DC-based vaccines, tumor antigens, gene-silencing, GM-CSF, Immunological Microenvironment
Abstract: Although animal studies have shown that tumor antigen (TA)-pulsed dendritic cell (DC)-based vaccines can mediate antitumor effects in vivo, human clinical trials utilizing this strategy have thus far had only modest success. In an effort to improve the efficacy of tumor vaccines, numerous investigators have explored the genetic engineering of DC to impart cytokine or TA-expression capability on DC. These efforts have focused on enhancing TA presentation and as well as subsequent T-cell activation and expansion. This chapter reviews recent progress in studies aimed to potentiate the efficacy of DC-based vaccines by genetic engineering of DCs with cDNAs encoding immuno-stimulatory cytokine-genes or TAs.
Export Options
About this article
Cite this article as:
Okada Hideho and Butterfield H. Lisa, Manipulation of Dendritic Cells for Tumor Immunity, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (2) . https://dx.doi.org/10.2174/187152307780598054
DOI https://dx.doi.org/10.2174/187152307780598054 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NGS of microRNAs Involved in Cardioprotection Induced by Sevoflurane Compared to Propofol in Myocardial Revascularization Surgery: The ACDHUVV-16 Clinical Trial
Current Medicinal Chemistry Multi-Target Directed Compounds with Antioxidant and/or Anti- Inflammatory Properties as Potent Agents for Alzheimer’s Disease
Medicinal Chemistry mTOR Targeted Cancer Chemoprevention by Flavonoids
Current Medicinal Chemistry Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Natural Products Based Anticancer Agents
Mini-Reviews in Organic Chemistry TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design Nifurtimox Hampered the Progression of Astroglioma <i>In vivo Via</i> Manipulating the AKT-GSK3β axis
Current Molecular Medicine Kinetic Study on the Effects of Extremely Low Frequency Electromagnetic Field on Catalase, Cytochrome P450 and Inducible Nitric Oxide Synthase in Human HaCaT and THP-1 Cell Lines
CNS & Neurological Disorders - Drug Targets Hypoxia Inducible Factor-1 in Cancer Immune Suppression
Current Immunology Reviews (Discontinued) The Antimalarial Drug Pyronaridine Inhibits Topoisomerase II in Breast Cancer Cells and Hinders Tumor Progression In Vivo
Clinical Cancer Drugs Neuropharmacological Aspects of Crocus sativus L.: A Review of Preclinical Studies and Ongoing Clinical Research
CNS & Neurological Disorders - Drug Targets Recent Advancements in 1,4-Disubstituted 1H-1,2,3-Triazoles as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Thyroid Hormone Modulation of Immunity: Its Participation in Chronic Stress-Induced Immune Alterations
Current Immunology Reviews (Discontinued) The Amyloid β-Protein Precursor and Alzheimers Disease. Therapeutic Approaches
Current Medicinal Chemistry - Central Nervous System Agents Marine Metabolites Overcoming or Circumventing Multidrug Resistance Mediated by ATP-Dependent Transporters: A New Hope for Patient with Tumors Resistant to Conventional Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Pyridinium Oxime Reactivators of Cholinesterase Inhibited by Diisopropyl- Fluorophosphate (DFP): Predictive Value of In-Vitro Testing for In-Vivo Efficacy
Mini-Reviews in Medicinal Chemistry Introduction: P2 Receptors
Current Topics in Medicinal Chemistry Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis
Current Pharmaceutical Design Carotenoids and Modulation of Cancer: Molecular Targets
Current Pharmacogenomics MicroRNAs: A Novel Therapeutic Target for Schizophrenia
Current Pharmaceutical Design